Amarin (AMRN) Stock: Buy, Sell, or Hold?
AMRN - Amarin Corp Plc
$12.35
-0.37 (-2.91%)
▼
5d:
-6.44%
30d:
-9.85%
90d:
-21.49%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When AMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AMRN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AMRN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AMRN is currently trading at $12.35, which is considered oversold relative to its 30-day fair value range of $13.23 to $14.15. From a valuation perspective, the stock is trading at a discount (Forward PE: -212.0) compared to its historical average (17.3). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, AMRN is in a downtrend. The price is currently testing key support at $12.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AMRN scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AMRN is in a downtrend. The price is currently testing key support at $12.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AMRN scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.23 -
$14.15
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (17/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($12.50)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.23 -
$14.15
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$12.45
Resistance Level
$13.90
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-212.00
Wall Street Target
$12.50
(-1.7%)
Revenue Growth (YoY)
-42.0%
Earnings Growth (YoY)
-94.2%
Profit Margin
-14.6%
PE vs Historical
-212.0 vs 17.3
CHEAP
Share & Embed Analysis
Last updated: October 02, 2026 3:58 PM ET
Data refreshes hourly during market hours. Next update: 4:58 PM
Data refreshes hourly during market hours. Next update: 4:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1325 | 48 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$159 | 46 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$279 | 57 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$389 | 55 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$238 | 48 HOLD |
